eShowcase: Nextrials and Vitalograph
Partnership puts pulmonary data in the hands of researchers when and where they need it
Partnership puts pulmonary data in the hands of researchers when and where they need it
Nextrials, Inc. (San Ramon, CA) is partnering with Vitalograph (Lenexa, KS, and Buckingham, UK) to deliver expedited access to pulmonary function data collected during clinical trials. The system works by closely integrating Nextrials' Prism clinical trial management system with the Vitalograph Spirotrac Centralized Spirometry System.
As a result, biotechnology and medical device researchers can quickly evaluate pulmonary lung function, potentially improving patient safety. For researchers, real-time access to study data also translates into enhanced workflow and efficiency. Ultimately, this results in reduced costs and quicker time to market for new therapies. As a result of the collaboration, sponsors have access to a single product that provides all relevant data including pulmonary function information, in real time across multiple test sites and multiple studies.
Nextrials, Inc., (925) 355-3000, www.nextrials.com
Vitalograph, (800) 255-6626, www.vitalograph.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.
